Survival rates of melanoma patients with sentinel diagnostics before and after the introduction of modern therapies (BRAF / MEK inhibition, anti-CTLA-4 antibodies, anti PD-1 antibodies).
- Conditions
- C43.9Malignant melanoma of skin, unspecified
- Registration Number
- DRKS00023405
- Lead Sponsor
- niversitätsmedizin Göttingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 972
Inclusion Criteria
Patient with sentinel biopsy
tumor thickness according to Breslow >/= 1 mm
Growth pattern not spitzoid
Exclusion Criteria
Tumor thickness according to Breslow < 1 mm
Growth pattern spitzoid
Adjuvant therapy with MAD
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival according to SN status and time period
- Secondary Outcome Measures
Name Time Method Recurrence-free survival according to SN status and time period